MEDIFAST (MED) Director Kiai Parsa Buys 72,487 Shares

What Happened Kiai Parsa, a director of MEDIFAST, reported open-market purchases (transaction code P) totaling 72,487 shares across Aug 19–20, 2026. Transactions reported: 28,538 shares @ $11.66 ($332,685) and 799 shares @ $11.66 ($9,314) on 8/19; 41,975 shares @ $11.60 ($487,065) and 1,175 shares @ $11.60 ($13,634) on 8/20. Aggregate consideration for these purchases is approximately $842,698. These were purchases (acquisitions) rather than sales.

Key Details

• Dates & prices: Aug 19, 2026 — 28,538 @ $11.66 (avg; actual $11.56–$11.80 per F4) and 799 @ $11.66; Aug 20, 2026 — 41,975 @ $11.60 (avg; actual $11.46–$11.77 per F5) and 1,175 @ $11.60.
• Total shares bought: 72,487; total cash paid: ≈ $842,698.
• Filing: Form 4 filed Aug 21, 2026, reporting transactions dated Aug 19–20. This filing timing appears to be within the typical 2-business-day reporting window.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: purchases were made through funds (Steamboat Capital Partners Master Fund, LP and Steamboat Capital Partners II, LP). Kiai is Managing Member of the advisor and GP; he may be deemed to have a pecuniary interest in those fund holdings but disclaims direct beneficial ownership except to the extent of that interest (F1–F3). Footnotes F4 and F5 disclose that the per-line prices are averages and give the actual price ranges for 8/19 and 8/20; detailed trade-by-trade prices are available on request.

Context

• These trades reflect fund-level purchases tied to Steamboat entities for which Parsa has managerial/pecuniary ties, not necessarily direct personal buys. For retail investors, purchases reported by insiders or affiliated funds can be informative but do not prove motive or future company performance.
• No options exercises, gifts, or tax-withholding events are reported here—only open-market purchases (P).